Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a fixed-dose combination with Roche’s CT-388, aiming to compete in the weight loss drug market. Zealand Pharma will receive $1.65 billion upfront and potential milestone payments, with shares of both companies rising after the announcement. The partnership will see Roche and Zealand jointly commercialize petrelintide in the U.S. and Europe, sharing profits and losses equally, while Roche will have exclusive commercialization rights in the rest of the world.
Full Article
At least one killed as firefighters battle Greece blaze for second day | Climate News
The worst blaze in the town of Keratea on the outskirts of Athens was contained but not out on Saturday, fire brigade spokesperson says.Wildfires in Greece, fueled by strong winds, have resulted in at least one death and significant destruction in Keratea, where evacuations continue amidst ongoing threats. Firefighters, supported by aerial units, battled the blaze while extreme weather disrupted ferry services and led to additional casualties on the island of Milos. Want More Context?...
Read more